ArticleCancer immunology, immunotherapy : CII2026
Integrated immunophenotypic and ProMisE molecular profiling as predictors of immune checkpoint inhibitor response in recurrent endometrial cancer.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs) are an important treatment option for recurrent endometrial cancer (EC); however, responses vary widely. Although the ProMisE molecular classification provides prognostic and predictive insights, it does not fully explain the heterogeneity of ICI outcomes. Further characterization of the tumor immune microenvironment (TIME) is required to refine biomarker development.
methodsWe retrospectively analyzed 72 patients with recurrent EC treated with ICIs. Immune markers, including CD8, CD68, CD163, CD47, CD276, PD-L1, and HLA class I, were quantified using digital pathology. Associations between immune markers, ICI response, and progression-free survival (PFS) were evaluated overall and within ProMisE molecular subtypes. In an exploratory supplementary analysis, Foxp3 immunostaining was performed in 51 cases with additional FFPE material available.
resultsResponders exhibited a more immunologically active TIME, characterized by increased CD8⁺ T-cell infiltration in the central tumor (CT), whereas non-responders showed enriched CD68⁺ tumor-associated macrophages at the invasive margin (IM) and higher CD47 expression. Distinct immune landscapes were observed across ProMisE subtypes. Mismatch repair-deficient (MMRd) tumors demonstrated higher intratumoral CD8+ infiltration, whereas p53-abnormal (p53abn) tumors showed a more immunosuppressive profile, including elevated CD163+ macrophage density and CD47 expression. Subtype-specific analyses revealed that PFS was associated with different immune determinants, including CD8+ T cell infiltration in MMRd, CD47 expression level in no specific molecular profile (NSMP), and CD68.IM in p53abn. In the Forkhead box P3 (Foxp3) subset, the CD8/Foxp3 ratio showed a stronger association with ICI response and PFS than Foxp3 alone.
conclusionsTumor immune phenotypes provide clinically relevant information complementary to ProMisE classification. Rather than indicating a single universal determinant, our results support a model in which cytotoxic T-cell infiltration and immunosuppressive pathways jointly shape ICI outcome in recurrent EC. Integrating ProMisE classification with immunological profiling may improve patient stratification of ICI benefits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.